In partnership with
January 22, 2026
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
Today’s edition starts with Congress pulling the hemp delay language and putting the market back on calendar math, with households and retailers absorbing the whiplash first. We track Chicago’s ban as market design dressed up as safety, the White House trying to treat rescheduling as a deliverable, and the legal risks showing up in contracts and courtrooms as trust gets tested upstream. Decoded Insight is our new essay on America’s two THC markets and the overdue middle path that tightens the rules where safety needs it and relaxes them where the regulated system keeps losing demand.
Today’s edition is supported by 1440 Media and Masterworks. To sponsor Policy, Decoded and reach the executives, investors, and policymakers who read this briefing, reply to this email and we will send details.
⏳ The hemp clock restarts
🏙️ Cities redraw the channel
⚖️ Two markets, one lane
Mind the gap.
Join over 4 million Americans who start their day with 1440 – your daily digest for unbiased, fact-centric news. From politics to sports, we cover it all by analyzing over 100 sources. Our concise, 5-minute read lands in your inbox each morning at no cost. Experience news without the noise; let 1440 help you make up your own mind. Sign up now and invite your friends and family to be part of the informed.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: Years ago, when I was doing health care policy work, a a mentor of mine said to me about an idea I had, “You’re taking an elephant gun to a mosquito.” He was not trying to be clever. He was saying the tool was bigger than the problem. I never forgot it.
That phrase keeps coming back as Congress tightens the federal hemp definition. States did not start complaining about intoxicating hemp because they felt like picking a fight. They complained because Washington opened a national lane and never built the guardrails. In the marijuana era, federal posture was plain. It was illegal. States that legalized did it with their eyes open. Then the Cole Memo years gave governors and regulators a practical map of what would draw federal heat, youth access, diversion, criminal enterprises, public lands, violence. Imperfect, political, still usable.
Hemp played out backwards. Congress declared hemp legal in 2018, drew the 0.3 percent delta-9 line, and then mostly vanished from the consumer product market. The gap became the business model. A lot of it was legitimate CBD commerce. A lot of it was intoxicating product that functioned like adult-use cannabis without adult-use rules. States were not only mad about bad products. They were mad about being handed liability for a national market Congress authorized and never organized.
Then some states did the hard thing. They regulated. They built age gates, dose caps, labeling rules, and enforcement lanes that actually work in the real world. They saw upside quickly, tax receipts, a lifeline for alcohol retailers and distributors, local brands that look like local jobs. They learned the downside too. You cannot run a clean program when product pours in across state lines and enforcement starts at the checkout counter instead of at the manufacturer.
Now Washington is intervening just as the category started to harden into an industry. That timing is why everyone feels whiplash.
💡 Why It Matters: Congress reached for the fastest tool it has, a definition that fits inside a spending bill. A per-container THC cap is meant to crush the gas station weed problem. It also has a blast radius that is going to be politically impossible to ignore.
Start with the people who never signed up for this fight. Pet owners using CBD to manage anxiety and seizures. Seniors buying balms and ointments for joint pain and sleep. Families who found a CBD routine that felt boring and safe and legal. Those are ordinary-life products, and ordinary-life products create ordinary voters. When shelves change overnight, the pressure shows up fast.
Then the calendar. Farmers decide what to plant long before Congress decides what it meant. Processors sign contracts before agencies issue guidance that anyone can rely on. Retailers do resets months ahead. A federal effective date lands in the middle of real cycles and changes behavior immediately. Hiring pauses. Inventory gets dumped. Investment gets shelved. The market routes around uncertainty because it has to.
There is another piece policymakers rarely say out loud. Not every intoxicating product in hemp was a bad actor product. Some operators built age gates, testing discipline, and channel controls that look a lot like alcohol compliance. A definition-based crackdown does not reward that effort. It does not distinguish careful from reckless. It draws a line and tells enforcement to sort out the mess.
That is the elephant gun problem. You hit the mosquito. You also hit everything in the vicinity.
🧠 THC Group Take: Washington legalized hemp and then left a national consumer market to govern itself, which guaranteed a patchwork that honest players could not police and bad actors could game at scale. Congress is now using a definition change as a shortcut for standards work, and the predictable result is demand shifting into illicit channels while enforcement pressure falls on the easiest targets, small retailers, local delivery, communities already familiar with uneven drug enforcement. A durable fix starts with federal ownership: an enforceable floor on manufacturing, testing, labeling, serving size, packaging, and age verification, backed by inspections, penalties, and a supply chain record that begins at the manufacturer. The floor also needs lane separation, clear protection for non-intoxicating CBD and topical uses, a disciplined low-dose intoxicating lane with tight dose and package limits, and a hard exclusion for synthetics and products built to evade the rules. Government can run that directly or delegate pieces to a credible standards and certification regime that platforms and major retailers will honor, because standards without consequences stay theoretical. Congress can keep firing the elephant gun and then cleaning up the collateral damage, or it can govern like it plans to live with the outcome.
Fast-moving headlines, flagged for what matters.
Hill leaders stripped the hemp delay language from the funding package, putting growers and retailers back on a hard countdown while planting decisions and shelf resets are already in motion. That move tells you the leverage is real, because only a few members can force edits when the bill must pass. It also tells you the federal government still has no replacement plan that looks like standards, inspection, and enforceable consequences. The industry gets the worst version of policy, a deadline with no rulebook. The next fight is not theory, it is calendar math and who gets blamed when product disappears or moves underground. (MJBizDaily)
The federal crackdown is framed as a clean hit on intoxicating products, and the spillover is already obvious. Seniors using topical balms for joints and sleep do not see themselves in the gas station gummy debate, and pet owners dealing with anxiety and seizures do not either. Retailers now have to choose between pulling products that have been stable for years or carrying them with legal ambiguity hanging overhead. This is how overbroad policy builds its own opposition, because the coalition expands beyond industry and into households. Congress can either write carveouts in a panic later or build standards now with dosage, labeling, testing, and age gates that actually separate categories. (Yahoo)
Chicago approved a citywide ban aimed at most hemp-derived THC products, with penalties reported up to $5,000 for covered sales outside licensed dispensaries. That is a market structure decision dressed up as consumer protection. Reporting points to an April 1st effective date, so the compliance scramble starts immediately for retailers, distributors, and brands that built age gating and testing programs. The city is also sending a message to Springfield that patchwork is the fallback when the state will not draw a clean statewide line. Once local bans start, they do not stay local. They turn into a template. (Chicago Sun-Times)
Curaleaf is shutting down its hemp-derived THC business as federal definitions tighten and national shelf ambitions get harder to defend. This matters because Curaleaf treated hemp as a real distribution strategy, spent brand equity on it, and still decided the risk was not worth the carry. When a scaled operator exits, the investor conversation changes overnight. Retailers also notice, because the biggest brands usually have the best lawyers and the best compliance teams. The signal is simple: uncertainty is no longer a speed bump, it is the business model. (Cannabis Equipment News)
Anheuser-Busch leadership is publicly brushing off hemp THC beverages, and nobody should confuse that tone with comfort. Big beverage companies do not spend oxygen on non-threats, especially when the fight is really about who owns the next social ritual and the shelf space that comes with it. The posture you are seeing is classic incumbent behavior: minimize in public, tighten the political coalition in private, and steer lawmakers toward a channel outcome that protects the three-tier system and keeps new intoxicants inside familiar gates. That is why the talking points lean hard on safety even when the real stakes are market structure and distribution power. The consequence is more pressure for rules that pick winners by channel, with mainstream retail pushed out and licensed systems positioned as the only “responsible” home. (Brewbound)
A Florida hemp cannabinoid producer sued Vertosa, alleging certain delta-9 emulsions were marketed as natural and hemp-derived while being sourced from cannabis-derived THC. The details will play out in court, and the broader impact hits now because buyers hate upstream ambiguity. Every contract clause that used to be boilerplate becomes a negotiation, including representations, audit rights, sampling, and indemnities. The downstream problem is trust, because a label stops functioning as a shortcut when the supply chain story can be contested. The clean operators end up paying the reputational bill for the ones who treated hemp like a costume. (BevNet)
Two pieces landed on the same point from different angles: the sector is racing to build a credible scientific and standards record before the federal clock runs out, and critics say the failure to unify around enforceable CBD standards helped invite the crackdown. Both things can be true at once. Serious operators spent years building state-by-state rules to fill the federal void, and state rules cannot fully solve an interstate market. Standards also require enforcement and consequences, and that takes government capacity or a real certification regime that retailers and platforms respect. The pressure is obvious now: show a credible, enforceable model fast, or watch Congress keep writing blunt definitions because nuance is not presented in an enforcement-ready package. (Business of Cannabis)
A Courier-Journal opinion piece by Kevin Sabet of SAM celebrates the hemp intoxicant ban as a public health victory and argues regulation is a dead end. The numbers he cites are serious, and his conclusion still misses the mechanics of access. Bans do not erase demand, they shift it into illicit markets and remove the compliant sellers who were easiest to inspect, test, and punish. That is the war on drugs lesson, and the enforcement footprint landed hardest on Black and brown communities, which is why prohibition rhetoric carries its own political baggage. If the goal is fewer poisonings, the adult move is standards with teeth, packaging limits, real age verification, dose rules, lab integrity, and enforcement aimed at evasion, not a press release that declares victory while the market reroutes. (Courier-Journal)
The White House is publicly banking credit for President Trump’s rescheduling order, and that is meant to turn Schedule III into a deliverable, not a maybe. Markets and state politicians hear that and start making plans. The constraint is still process, because administrative records take time and lawsuits love high-profile targets. The practical read is that Washington is trying to compress the timeline through political pressure rather than procedural shortcuts. Expect louder messaging and quiet delays, sometimes in the same week. (Marijuana Moment)
ATF is moving to narrow how it decides when drug use makes someone a prohibited firearm purchaser, steering away from one-off clues and toward evidence of current, regular use that covers the present time. That change matters because the old approach let a stray admission or a single data point turn into a lifetime problem, including for marijuana users in legal states who still collide with federal law the minute they touch a Form 4473. This is happening while courts keep chewing on how far the unlawful user ban can go and still look constitutional and workable in real life. The tension stays the same for consumers and employers: cannabis remains federally illegal, and the background check system still forces a yes or no question that people answer with their freedom on the line. The move narrows one tripwire and leaves the broader conflict unresolved, which is Washington in a nutshell. (Marijuana Moment)
Filings show SAM Action supplied the entire early bankroll for the Massachusetts effort to recriminalize adult-use cannabis, totaling $1.55 million so far. That is not grassroots energy, it is a national campaign deciding Massachusetts is a winnable terrain fight. The fraud claims around signatures add risk, because ballot procedure can become the main battlefield before voters ever reach the merits. Massachusetts also has a mature market and a lived normalcy factor that is hard to unwind. The money signals intent, and it signals the campaign will be run like a professional opposition project, not a symbolic petition drive. (Cannabis Business Times)
Virginia lawmakers filed new bills to stand up the adult-use retail market the state legalized years ago and then left hanging in midair. The key change is time, because the proposals put real dates on licensing and set an earliest path to sales that would begin no earlier than November 1st. That forces everyone to stop playing pretend, including local governments, would-be licensees, and the regulator that has been stuck managing legal possession alongside an unregulated sales reality. The politics stay sharp because prior frameworks died at the governor’s desk, so this round gets written with veto risk and public safety optics baked into every line. If this moves, the real fight shifts fast to market design, who gets in, how fast, and whether the rules build a functioning channel or another slow-motion stalemate. (Ganjapreneur)
Nebraska lawmakers introduced legislation to consolidate the voter-passed medical initiatives and fill in the missing framework. The bill builds a registry, defines qualifying conditions, requires recommending practitioners to register, and bars physician financial ties to licensees. It also gives the Medical Cannabis Commission real authority, including penalties, recalls, and seed-to-sale tracking, plus shared staffing with the Liquor Control Commission. Advocates say this narrows access beyond what voters approved and empowers a Commission they already distrust. The vote threshold makes it a straight test of political will: implementation discipline or rollback by design. (Lincoln Journal Star)
Colorado’s Attorney General announced a new settlement after MC Global Holdings allegedly violated a prior consumer protection agreement tied to deceptive cannabis marketing. The state says the company kept soliciting sales and implied restrictions were narrower than they were, which is exactly the behavior that turns regulators from patient to punitive. Colorado also flagged out-of-state testing issues and inconsistent claims about where operations were based. The fine starts at $75,000 and can escalate sharply with another violation. The signal to the market is clean: settle once and you are on supervision, not off the hook. (Regulatory Oversight)
Federal action at a Maine medical storefront and a separate mortgage fraud grow-house case point to the same system vulnerability: ownership, money, and ordinary transactions being used as a front door for illicit activity. A license on paper does not mean much when the real controller is hidden, and a residential mortgage does not look suspicious until the house burns. The reputational cost lands on the legitimate market, because every headline becomes fuel for broader crackdowns. The enforcement lesson for regulators is boring and consistent: beneficial ownership scrutiny and financial transparency do more than flashy raids. The political lesson is harsher: when a medical program looks porous, lawmakers stop listening to nuance. (Central Maine)
The deeper pattern behind today’s moves — and why it matters next.
Dalio: “Stocks Only Look Strong in Dollar Terms.” Here’s a Globally Priced Alternative for Diversification.
Ray Dalio recently reported that much of the S&P 500’s 2025 gains came not from real growth, but from the dollar quietly losing value. Reportedly down 10% last year!
He’s not alone. Several BlackRock, Fidelity, and Bloomberg analysts say to expect further dollar decline in 2026.
So, even when your U.S. assets look “up,” your purchasing power may actually be down.
Which is why many investors are adding globally priced, scarce assets to their portfolios—like art.
Art is traded on a global stage, making it largely resistant to currency swings.
Now, Masterworks is opening access to invest in artworks featuring legends like Banksy, Basquiat, and Picasso as a low-correlation asset class with attractive appreciation historically (1995-2025).*
Masterworks’ 26 sales have yielded annualized net returns like 14.6%, 17.6%, and 17.8%.
They handle the sourcing, storage, and sale. You just click to invest.
Special offer for my subscribers:
*Based on Masterworks data. Investing involves risk. Past performance is not indicative of future returns. Important Reg A disclosures: masterworks.com/cd.
From the hearing room to the comment section — we’re watching it all.
🧠 Legal cannabis still struggles with trust because consumers were promised safety and consistency and often experience confusing labels and uneven product performance instead. When the rules are visible and enforced, the regulated market earns credibility and repeat behavior. When they are not, price and convenience pull demand back toward informal channels and hand opponents an easy political argument. (GreenState)
🥤 Nowadays hired a former TTB official to run regulatory affairs, which tells you they expect hemp drinks to be judged like alcohol: labels you can enforce, channels you can audit, consequences you can explain to a legislator. The category is maturing because the risk has matured, and serious brands are staffing up for a rules fight that will be won by the people who can offer enforceable guardrails. (PR Newswire)
👩🌾 A new global study found that when cannabis is legal, women participate in cultivation more and capture more of the economic upside. Rules change the risk profile, and when the risk drops, opportunity stops being reserved for the people most willing to gamble. Policymakers who want a fairer industry should treat stable licensing and predictable enforcement as participation policy, not just business regulation. (Cal Poly Humboldt)